10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Mr. Serge Saxonov est le Chief Executive Officer de 10X Genomics Inc, il a rejoint l'entreprise depuis 2012.
Quelle est la performance du prix de l'action TXG ?
Le prix actuel de TXG est de $22.09, il a augmenté de 3.36% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de 10X Genomics Inc ?
10X Genomics Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de 10X Genomics Inc ?
La capitalisation boursière actuelle de 10X Genomics Inc est de $2.8B
Est-ce que 10X Genomics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 16 analystes ont établi des notations d'analystes pour 10X Genomics Inc, y compris 5 achat fort, 5 achat, 13 maintien, 0 vente et 5 vente forte